Oncotelic Therapeutics, Inc. 8-K Filing
Ticker: OTLC · Form: 8-K · Filed: Dec 30, 2025 · CIK: 908259
| Field | Detail |
|---|---|
| Company | Oncotelic Therapeutics, Inc. (OTLC) |
| Form Type | 8-K |
| Filed Date | Dec 30, 2025 |
| Pages | 4 |
| Reading Time | 4 min |
| Key Dollar Amounts | $25,000, $0.10, $1.00, $0.12, $1.25 |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Oncotelic Therapeutics, Inc. (ticker: OTLC) to the SEC on Dec 30, 2025.
What are the key financial figures in this filing?
Key dollar amounts include: $25,000 (he "Notes"), in the principal amount of $25,000.00, bearing annual interest at the rate); $0.10 (otelic's Common Stock (conversion price $0.10 per share) or 25,000 shares of common s); $1.00 (ned subsidiary at a conversion price of $1.00 per share, both subject to applicable a); $0.12 (ne share of Oncotelic's Common Stock at $0.12 per share or 25,000 warrants (the "Edge); $1.25 (mmon stock of EdgePoint Common Stock at $1.25 per share. The exercise price of each W).
How long is this filing?
Oncotelic Therapeutics, Inc.'s 8-K filing is 4 pages with approximately 1,067 words. Estimated reading time is 4 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 1,067 words · 4 min read · ~4 pages · Grade level 11 · Accepted 2025-12-30 17:00:50
Key Financial Figures
- $25,000 — he "Notes"), in the principal amount of $25,000.00, bearing annual interest at the rate
- $0.10 — otelic's Common Stock (conversion price $0.10 per share) or 25,000 shares of common s
- $1.00 — ned subsidiary at a conversion price of $1.00 per share, both subject to applicable a
- $0.12 — ne share of Oncotelic's Common Stock at $0.12 per share or 25,000 warrants (the "Edge
- $1.25 — mmon stock of EdgePoint Common Stock at $1.25 per share. The exercise price of each W
Filing Documents
- form8-k.htm (8-K) — 47KB
- 0001493152-25-029634.txt ( ) — 204KB
- otlc-20251223.xsd (EX-101.SCH) — 3KB
- otlc-20251223_lab.xml (EX-101.LAB) — 33KB
- otlc-20251223_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 3KB
02 below,
Item 3.02 below, Item 3.02 Unregistered Sales of Equity Securities. On December 23, 2025, Oncotelic Therapeutics, Inc. (the " Company ") completed entering into subscription agreements with certain accredited investors (" Subscription Agreement "), whereby the Company issued a total of 32 units (" Units ") to 21 accredited investors .Each Unit is part of an of f ering (the " O ffe r ing " ) of up to Five Hundre d ( 500 ) unit s (th e "Units" ) bein g conducte d b y Maker . Each Unit consists of one note issued by the Company (a "Note" and collectively, the "Notes"), in the principal amount of $25,000.00, bearing annual interest at the rate of 12% and due and payable on the 2-year anniversary of the final closing of the Offering. Each Note will be convertible into up to 250,000 shares of Oncotelic's Common Stock (conversion price $0.10 per share) or 25,000 shares of common stock ("EdgePoint Common Stock") of EdgePoint AI, Inc. (EdgePoint"), our consolidated minority owned subsidiary at a conversion price of $1.00 per share, both subject to applicable anti-dilution provisions. Each Unit will also consist of 250,000 (the "Warrants") each to purchase one share of Oncotelic's Common Stock at $0.12 per share or 25,000 warrants (the "EdgePoint Warrants") to purchase each one share of common stock of EdgePoint Common Stock at $1.25 per share. The exercise price of each Warrant or EdgePoint Warrant will be subject to applicable anti-dilution provisions set forth therein and, except as set forth in the next succeeding sentence, each Warrant will be exercisable for two years after issuance. Further, in exchange for the Company's 2023 PPM Note, the Company shall consider the old 2023 note as paid off and the contribution towards the new Notes as fully paid for, with all the terms noted above. The prior 2023 issued warrants shall continue to vest as before and on the same terms and conditions contained in such prior issued warrant, for an additional period of two years exten